We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+5.44%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$558M
AUM Growth
+$124M
Cap. Flow
+$99.9M
Cap. Flow %
17.91%
Top 10 Hldgs %
37.3%
Holding
93
New
18
Increased
51
Reduced
4
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$27.2M
2
MDT icon
Medtronic
MDT
+$25.2M
3
CI icon
Cigna
CI
+$8.15M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$7.58M
5
AET
Aetna Inc
AET
+$7M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$24.6M
2
UNH icon
UnitedHealth
UNH
+$14.8M
3
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$11.7M
4
BMY icon
Bristol-Myers Squibb
BMY
+$9.64M
5
ABBV icon
AbbVie
ABBV
+$4.46M

Sector Composition

Rank Sector Weight
1 Healthcare 75.87%
2 Industrials 2.28%
3 Financials 1.34%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$165B
$28.2M 5.05%
340,000
+9,000
+3% +$701K
MRK icon
2
Merck
MRK
$322B
$27.5M 4.93%
+497,800
New +$27.2M
MDT icon
3
Medtronic
MDT
$112B
$26.5M 4.74%
+415,000
New +$25.2M
ITMN
4
DELISTED
INTERMUNE INC
ITMN
$23.8M 4.26%
538,000
+128,000
+31% +$4.71M
MCK icon
5
McKesson
MCK
$104B
$22.2M 3.97%
119,000
+27,500
+30% +$4.89M
BIIB icon
6
Biogen
BIIB
$30.9B
$18.9M 3.39%
60,000
+4,750
+9% +$1.43M
THOR
7
DELISTED
THORATEC CORPORATION
THOR
$17.2M 3.08%
492,200
+91,200
+23% +$3.04M
ABBV icon
8
AbbVie
ABBV
$465B
$15.5M 2.78%
275,000
-85,000
-24% -$4.46M
AGN
9
DELISTED
Allergan plc
AGN
$14.7M 2.63%
65,750
+9,500
+17% +$1.97M
CELG
10
DELISTED
Celgene Corp
CELG
$13.7M 2.46%
160,000
+6,000
+4% +$456K
AMGN icon
11
Amgen
AMGN
$209B
$13.6M 2.44%
115,000
– –
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
$13.4M 2.4%
85,750
+37,250
+77% +$5.88M
TMO icon
13
Thermo Fisher Scientific
TMO
$214B
$12.7M 2.29%
108,000
+750
+0.7% +$88.3K
AVDL
14
DELISTED
Avadel Pharmaceuticals
AVDL
$11.6M 2.08%
775,000
+25,000
+3% +$302K
HUM icon
15
Humana
HUM
$43.9B
$9.26M 1.66%
72,500
+7,000
+11% +$829K
CVS icon
16
CVS Health
CVS
$135B
$9.14M 1.64%
121,250
+8,250
+7% +$624K
CI icon
17
Cigna
CI
$78.4B
$8.74M 1.57%
+95,000
New +$8.15M
ISRG icon
18
Intuitive Surgical
ISRG
$127B
$8.67M 1.55%
189,450
+22,950
+14% +$1.01M
COO icon
19
Cooper Companies
COO
$14.2B
$8.54M 1.53%
252,000
+10,000
+4% +$330K
HRC
20
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$8.09M 1.45%
+195,000
New +$7.58M
ATHN
21
DELISTED
Athenahealth, Inc.
ATHN
$7.79M 1.4%
62,250
+42,750
+219% +$5.52M
ILMN icon
22
Illumina
ILMN
$29.5B
$7.68M 1.38%
44,204
+514
+1% +$76.7K
SRGA
23
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$7.61M 1.37%
58,333
+35,454
+155% +$4.5M
AET
24
DELISTED
Aetna Inc
AET
$7.5M 1.34%
+92,500
New +$7M
PCRX icon
25
Pacira BioSciences
PCRX
$1.04B
$7.14M 1.28%
77,750
+16,750
+27% +$1.28M
1
2 3 4

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q2 2014 Portfolio in Review

As of Q2 2014, Rock Springs Capital Management held 93 positions worth $558M, up 29% from $434M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Rock Springs Capital Management deployed $99.9M of net new capital in Q2 2014, opening 18 new positions and adding to 51 existing holdings. Its largest new stake was Merck: 497,800 shares worth $27.5M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 79% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was AbbVie, an estimated $4.46M trimmed.

  • Rock Springs Capital Management's largest Q2 2014 buy was Merck: 497,800 shares worth $27.5M.
  • Rock Springs Capital Management added most to Alexion Pharmaceuticals in Q2 2014, an estimated $5.88M increase.
  • Rock Springs Capital Management's biggest Q2 2014 reduction was AbbVie, cutting an estimated $4.46M.
  • Rock Springs Capital Management fully exited Johnson & Johnson in Q2 2014, selling an estimated $24.6M.
  • Rock Springs Capital Management's ten largest holdings make up 37% of its $558M portfolio in Q2 2014.
  • Rock Springs Capital Management opened 18 new positions and closed 15 in Q2 2014.
  • Rock Springs Capital Management's portfolio value rose 29% quarter-over-quarter to $558M.

Based on Rock Springs Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.